U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07431476) titled 'Brimonidine 0.33% for Rosacea-Related Facial Erythema' on Dec. 07, 2025.
Brief Summary: This study looks at whether a topical gel called 0.33% brimonidine can reduce persistent facial redness caused by rosacea. The study was carried out in two parts.
In the first part, the gel was applied to only one side of each participant's face, while the other side received a placebo (a non-active gel). Redness was measured before and after application to see the immediate (short-term) effect.
In the second part, participants used brimonidine gel on both sides of the face once daily for one month. Redness and visible blood vessel changes were...